
Fanregratinib shows strong Phase II results for advanced intrahepatic cholangiocarcinoma, advancing regulatory review in China.
HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 mont...


